Lukas Hainz

Walgreens, one of the nation’s largest retail pharmacy chains, is embarking on a monumental journey to transform its clinical trials business. This bold move, initiated in June 2022, leverages Walgreens' nationwide retail presence and extensive patient data to tap into the burgeoning p

The biopharmaceutical industry has long faced hurdles integrating advanced manufacturing technologies (AMTs) into commercial biomanufacturing. Despite the clear benefits of AMTs, including enhanced efficiency, scalability, and product quality, adoption rates remain sluggish. This article seeks to

In an exciting development, Scorpius Holdings has been selected as a member of the Biomedical Advanced Research and Development Authority’s (BARDA) Rapid Response Partnership Vehicle (RRPV). This collaboration is expected to significantly enhance BARDA’s mission to accelerate the development of med

RedHill Biopharma Ltd., known for its focus on gastrointestinal and infectious diseases, has recently achieved compliance with Nasdaq's minimum bid price requirement. This milestone ensures that the specialty biopharmaceutical company will continue to be listed on the Nasdaq Capital Market, a

Autoimmune diseases, affecting millions of people worldwide, present a unique challenge where the body's immune system mistakenly attacks its tissues. Existing treatments primarily rely on immunosuppressants, which often come with severe side effects and don’t always offer a cure. Enter Candid

Enhancing Manufacturing Capabilities Novartis is making significant strides in its efforts to expand manufacturing capabilities to meet the growing demand for radiopharmaceutical therapies aimed at treating cancer. To achieve this, the company is not only expanding an existing facility in

Arsenal Biosciences, commonly known as ArsenalBio, has achieved a remarkable milestone by securing $325 million in a Series C funding round. This significant financial boost arrives amid a challenging year for biotech investments, particularly in the cell and gene therapy sectors. The raised

Sanofi, a leading pharmaceutical company, recently announced the results of its clinical trials for tolebrutinib, an experimental drug targeting multiple sclerosis (MS). The mixed outcomes have generated a buzz within the medical and investment communities. While the drug did not outperform an

Immix Biopharma, Inc. (Nasdaq: IMMX) recently announced a significant expansion of its clinical trial sites across the United States for the NEXICART-2 study, focusing on relapsed/refractory AL Amyloidosis. This expansion aims to provide broader patient access to innovative therapy options and

In a significant breakthrough for cancer treatment options, Tanvex BioPharma USA, Inc. ("Tanvex" or the "Company") announced that the FDA has approved their biosimilar product NYPOZI (filgrastim-txid) and accepted their Biologics License Application (BLA) for TX-05. These